March 20, 2025 - 10:26
Avalo Therapeutics has announced its financial results for 2024, highlighting significant updates regarding its ongoing clinical trials and organizational changes. The company is eagerly anticipating topline data from the Phase 2 LOTUS Trial of AVTX-009, which is being investigated for the treatment of hidradenitis suppurativa. This crucial data is expected to be released in 2026, marking an important milestone in Avalo's research and development efforts.
In a strategic move to bolster its leadership team, Avalo has appointed Jennifer Riley as the Chief Strategy Officer. Her expertise is expected to enhance the company's strategic direction as it navigates the complex landscape of biotechnology.
As of December 31, 2024, Avalo reported having approximately $135 million in cash reserves. This financial position is projected to provide sufficient runway into at least 2027, allowing the company to continue its focus on advancing innovative treatments for immune dysregulation.
